What If Endometriosis Is Not Just Hormonal? Scientists Are Looking at Bacteria

Key Takeaways

• Bacterial factors, especially Fusobacterium, linked to 64% of endometriosis cases
• Bacteria may trigger inflammation via LPS and TLR4, promoting lesion formation
• Antibiotic treatment reduced lesions in mouse models, hinting at non‑hormonal therapy
• Diagnosis still delayed 8‑12 years; Latina women face later, more severe diagnoses
• Hormonal and immune dysregulation remain central, now considered alongside microbiome

Pulse Analysis

Endometriosis affects roughly one in ten women of reproductive age, yet its origins have remained elusive. Traditional models—retrograde menstruation, coelomic metaplasia, and stem‑cell theories—explain tissue displacement but fail to account for why only a minority develop the disease. Recent advances in next‑generation sequencing have uncovered a surprising microbial presence in the uterus, prompting researchers to explore a bacterial component. The focus has sharpened on Fusobacterium, detected in nearly two‑thirds of endometriosis patients, where its endotoxins appear to ignite Toll‑like receptor 4 pathways, amplifying the chronic inflammation that fuels ectopic lesion growth.

Mechanistic studies reveal that Fusobacterium‑derived lipopolysaccharide recruits macrophages, polarizing them toward an M2 phenotype that secretes transforming growth factor‑beta. This cytokine milieu drives endometrial fibroblasts to become myofibroblasts—cells adept at adhering, migrating, and proliferating outside the uterus. In mouse models, antibiotics aimed at eradicating Fusobacterium markedly reduced lesion size, offering a tantalizing proof‑of‑concept for non‑hormonal intervention. While these preclinical results are promising, translating them to human patients demands caution; broad‑spectrum antibiotics could disrupt beneficial microbiota and the relevance of animal data to complex human disease remains uncertain.

The potential shift toward microbiome‑targeted therapies arrives amid persistent diagnostic delays—averaging a decade—and stark disparities for Latina women, who are diagnosed later and present with more advanced stages. Integrating bacterial insights with established hormonal and immune pathways could accelerate biomarker development, enabling earlier detection and personalized treatment. As the field balances optimism with rigor, the emerging bacterial narrative may finally provide the missing piece in a puzzle that has long sidelined women’s health.